FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies

Certara’s Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this BioSpace article about the FDA’s Complete Response Letter for the Lykos Therapeutics’s MDMA therapy for PTSD. Read the article to get her thoughts on the gaps in Lykos’ data package and how psychedelic drug developers can avoid these pitfalls.